Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Phase 2

Not yet recruiting

Conditions: T-cell Lymphoma
T-cell Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia

Interventions: Drug: Dexamethasone
Drug: Vincristine
Drug: Daunorubicin
Drug: Calaspargase pegol
Drug: Venetoclax
Drug: Bortezomib
Drug: Dasatinib
Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Nelarabine
Drug: Methotrexate
Drug: Thioguanine

First Posted Date: 2024-04-30

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 145

Registration Number: NCT06390319

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL

Phase 2

Not yet recruiting

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: Vincristine
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Venetoclax
Drug: Inotuzumab ozogamicin
Drug: 6-mercaptopurine
Drug: Blinatumomab
Drug: Methotrexate
Drug: Cytarabine
Drug: Prednisone

First Posted Date: 2024-04-26

Last Posted Date: 2024-04-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 53

Registration Number: NCT06387121

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Phase 2

Not yet recruiting

Conditions: Classic Hodgkin Lymphoma
Autologous Stem Cell Transplant

Interventions: Drug: Pembrolizumab
Procedure: Autologous stem cell transplant
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan

First Posted Date: 2024-04-22

Last Posted Date: 2024-04-22

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 28

Registration Number: NCT06377540

Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory Acute Leukemia

Phase 1

Not yet recruiting

Conditions: Relapsed/refractory KMT2A-r Acute Leukemia
Relapsed/refractory NUP98-r Acute Leukemia
Relapsed/refractory NPM1-m Acute Leukemia

Interventions: Drug: Ziftomenib
Drug: Cytarabine
Drug: Fludarabine

First Posted Date: 2024-04-19

Last Posted Date: 2024-10-28

Lead Sponsor: LLS PedAL Initiative, LLC

Target Recruit Count: 20

Registration Number: NCT06376162

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

Phase 3

Recruiting

Conditions: ETP-ALL

Interventions: Drug: Cytarabine
Drug: Homoharringtonine
Drug: Vindesine
Drug: venetoclax
Drug: Daunorubicin
Drug: cyclophosphamide
Drug: G-CSF
Drug: Dexamethasone
Drug: L-ASP

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-29

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 81

Registration Number: NCT06361329

Locations: 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Ma-Spore ALL 2020 Study

Phase 2

Recruiting

Conditions: B Lymphoblastic Leukemia

Interventions: Drug: Prednisolone
Drug: Dexamethasone
Drug: Vincristine
Drug: Methotrexate
Drug: L-Asparaginase
Drug: Pegylated asparaginase
Drug: Erwinase
Drug: Dasatinib
Drug: Cytarabine
Drug: Imatinib
Drug: Cyclophosphamide
Drug: Mercaptopurine
Drug: Rituximab
Drug: Thioguanine
Drug: Doxorubicin
Drug: Fludarabine

First Posted Date: 2024-03-28

Last Posted Date: 2024-03-28

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 500

Registration Number: NCT06336395

Locations: 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Phase 2

Recruiting

Conditions: Relapse/Recurrence
C-KIT Mutation
Core Binding Factor Acute Myeloid Leukemia
AML, Childhood
Refractory AML

Interventions: Drug: Avapritinib
Drug: Azacitidine Injection
Drug: Decitabine Injection
Drug: Idarubicin Hydrochloride
Drug: Cytarabine
Drug: Granulocyte Colony-Stimulating Factor

First Posted Date: 2024-03-19

Last Posted Date: 2024-08-22

Lead Sponsor: Children's Hospital of Soochow University

Target Recruit Count: 50

Registration Number: NCT06316960

Locations: 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳
Kaifeng Children's Hospital, Kaifeng, Henan, China
🇨🇳
Third Xiangya Hospital of Central South University, Changsha, Hunan, China

and more 9 locations

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

First Posted Date: 2024-03-19

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 171

Registration Number: NCT06317662

Revumenib in Combination With 7+3 + Midostaurin in AML

Phase 1

Not yet recruiting

Conditions: AML With Gene Mutations
AML
Leukemia
AML, Adult
Acute Myeloid Leukemia

Interventions: Drug: Revumenib
Drug: Midostaurin
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-21

Lead Sponsor: Maximilian Stahl, MD

Target Recruit Count: 22

Registration Number: NCT06313437

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Phase 4

Not yet recruiting

Conditions: Lymphoblastic Lymphoma
Mixed Phenotype Acute Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Dexamethasone
Drug: Vincristine
Drug: Daunorubicin
Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Drug: Methotrexate
Drug: Cytarabine

First Posted Date: 2024-03-04

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 850

Registration Number: NCT06289673

Locations: 🇺🇸
United States, Tennessee St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy